Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-05-24
2005-05-24
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252160, C514S257000
Reexamination Certificate
active
06897216
ABSTRACT:
Compounds having the structural formula Ior a pharmaceutically acceptable salt thereof, whereinR is optionally substituted phenyl, cycloalkenyl, or heteroaryl;X is alkylene or —C(O)CH2—;Y is —N(R2)CH2CH2N(R3)—, —OCH2CH2N(R2)—, —O—, —S—, —CH2S—, —(CH2)2—NH—, or optionally substituted m and n are 2-3, and Q is nitrogen or optionally substituted carbon; andZ is optionally substituted phenyl, phenylalkyl or heteroaryl, diphenylmethyl, R6—C(O)—, R6—SO2—, R6—OC(O)—, R7—N(R8)—C(O)—, R7—N(R8)—C(S)—, phenyl-CH(OH)—, or phenyl-C(═NOR2)—; or when Q is CH, phenylamino or pyridylamino; orZ and Y together are substituted piperidinyl or substituted phenyl; andR2, R3, R6, R7, and R8are as defined in the specification are disclosed, their use in the treatment of Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them; also disclosed are a processes for preparing intermediates useful for preparing compounds of formula I.
REFERENCES:
patent: 5565460 (1996-10-01), Suzuki et al.
patent: 0 217 748 (1991-02-01), None
patent: WO 9501356 (1995-01-01), None
patent: WO 9705138 (1997-02-01), None
patent: WO 9852568 (1998-11-01), None
Baraldi et al.,J. Med. Chem., 39(1996), p. 1164-1171.
Seela et al,Helvetica Chimca Acta, 69(1986), p. 1602-1613.
Ungerstedt et al,Brian Research, 24(1970), p. 485-493.
Ungerstedt,Eur. J. Pharmacol., 5(1968), p. 107-110.
Adami et al,Br. J. Pharmacol., 126,(Mar. 1999), 283P.
Boyle Craig D.
Chackalamannil Samuel
Greenlee William J.
Lindo Neil
Neustadt Bernard R.
Magatti Anita W.
Raymond Richard L.
Schering Corporation
LandOfFree
Adenosine A2a receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adenosine A2a receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adenosine A2a receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3376005